Clinical Trial Update: Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial comparing polyethylene glycol interferon alfa-2b (PEG Intron) to interferon alfa-2b (INTRON A) for newly diagnosed chronic myelogenous l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• Intron A (interferon alfa-2b)
• PEG Intron (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Myelogenous Leukemia | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-08-12